Funder
National Natural Science Foundation of China
International Science & Technology Cooperation Program of China
Health Department Foundation of Hunan Province
The New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference33 articles.
1. Bakheit AH, Abd-Elgalil AA, Mustafa B, Mustafa B, Haque A, Wani TA. Telmisartan. Profiles Drug Subst Excip Relat Methodol. 2015;40:371–429.
2. Deppe S, Boger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol. 2010;6:863–71.
3. Nishino A, Kato Y, Igarashi T, Sugiyama Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. Drug Metab Dispos. 2000;28:1146–8.
4. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev. 2002;54:1311–31.
5. Ishiguro N, Maeda K, Kishimoto W, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006;34:1109–15.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献